by A number of factors such as the growing awareness among youth about alcohol and drug addiction problems, surging technological advancements in drug of abuse (DOA) testing products, and soaring implementation of government initiatives for reducing the consumption of illicit drug use will drive the European DOA testing market at a CAGR of 9.6% during the forecast period (2018–2023).
The offering segment of the European DOA testing market is bifurcated into products and services. Of these, the products category generated the higher revenue in 2017, due to the soaring awareness about DOA testing devices and the increasing number of technologically advanced products in Europe. Whereas, the services category is expected to witness the faster growth during the forecast period, due to the rising practice of drug testing at workplaces and the burgeoning focus of market players on providing technologically advanced products to the European populace.
Further, the sample type segment of the European DOA testing market is categorized into hair, saliva, urine, and others. Under this segment, the urine category generated the highest revenue in 2017, as it is the most used sample for DOA testing in hospitals, workplaces, and laboratories. Whereas, the saliva category is expected to demonstrate the fastest growth during the forecast period. This will be due to the extensive use of saliva in criminal justice settings for detecting heroin, cannabis, cocaine, ethanol, amphetamine, benzodiazepines, methamphetamine, and barbiturates.
Geographically, the U.K. accounted for the largest share in the European DOA testing market in 2017, and it is also expected to exhibit the fastest growth throughout the forecast period. This can be credited to the surging incidence of drug abuse and escalating awareness about DOA testing in the country. According to the Office for National Statistics, cannabis was the most common drug used among the people of the U.K. between March 2019 and March 2020. In the country, around 7.8% of individuals within the age group of 16–59 years were using this drug during the same period.
